Solid Δ9-tetrahydrocannabinol (Δ9-THC) compositions
AssigneeCanna Chemistries LLC
InventorsEmily Rigsbee, David T. Jonaitis, Nathan Schultheiss, Lloyd Steven Miller
Life of this patent
Estimating the term…
Loading patent…
AssigneeCanna Chemistries LLC
InventorsEmily Rigsbee, David T. Jonaitis, Nathan Schultheiss, Lloyd Steven Miller
Estimating the term…
The invention relates to a solid Δ9-THC composition containing Δ9-THC and a powder former and having a molar ratio of Δ9-THC to powder former to form a flowable Δ9-THC powder. The powder former is selected from the group consisting of adenine, aspartame, caffeine, lactose, mannitol, nicotinamide, β-nicotinamide adenine dinucleotide, pipecolic acid, saccharin, aspartic acid, glutamic acid, glutamine, histidine, leucine, methionine, phenylalanine, proline, serine, tryptophan, valine, Epigallocatechin Gallate (EGCG), 2-Hydroxypropyl-beta-cyclodextrin (HPbCD), and Trimethyl-beta-cyclodextrin (TOMBC) and mixtures thereof. The invention also relates to methods of making a solid Δ9-THC composition of the invention. The Δ9-THC may be synthetic Δ9-THC or may be extracted Δ9-THC. The invention provides pharmaceutical or nutraceutical composition containing a solid Δ9-THC composition of the invention and a pharmaceutically- or nutraceutically-acceptable carrier where Δ9-THC is present in a pharmaceutically or nutraceutically effective amount. The invention also provides methods of treating a disease, disorder, or condition by administering to a patient in need thereof a therapeutically effective amount of a solid Δ9-THC composition. A solid Δ9-THC composition of the invention may also be incorporated into food and beverage products.
A solid Δ9-THC composition comprising Δ9-tetrahydrocannabinol (THC) and a powder former and having a molar ratio of Δ9-THC to powder former to form a flowable Δ9-THC powder and wherein the powder former is β-nicotinamide adenine dinucleotide and epigallocatechin gallate.
A method of making a solid Δ9-tetrahydrocannabinol (THC) composition comprising the step of combining Δ9-THC with a powder former under conditions and in a molar ratio to form a flowable Δ9-THC powder, wherein the powder former is β-nicotinamide adenine dinucleotide and epigallocatechin gallate.
Dependencies are inferred from the claim text.